CCL2 and pulmonary arterial hypertension: In line with this, resveratrol also counteracts downstream events that are synergistically induced by Ang II and TNF-α in experimental acute pulmonary thromboembolism and pulmonary artery hypertension, including activation of p38MAPK, NF-kB, and monocyte chemoattractant protein-1 (MCP-1) [185,186].